The global cyclosporine market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Cyclosporine works by suppressing the immune system’s responses further preventing the immune system from attacking healthy tissues. The major factor attributed to the market growth includes the rising prevalence of target diseases that include inflammatory and autoimmune diseases, all over the globe. According to the World Psoriasis Day consortium, around 25 million people globally that account for 2 to 3% of the total population have psoriasis. The high burden of disease and the emergence of multi-drug resistant pathogens have been augmenting the market growth. Further, a strong product pipeline, and persuasive government legislation related to psoriasis awareness are a few pivotal factors boosting the growth of the market.

Further, the growing uses of the drug to treat autoimmune diseases such as multiple sclerosis and rheumatoid arthritis is expected to boost the market growth. In addition, the development of different topical, as well as sustained release formulations using generic drugs to enhance ease of drug delivery and improve therapeutic efficacy at the desired site, are likely to propel the growth of the global cyclosporine market during the forecast period. Adding to this, the need for efficient therapies and competition among new market players is expected to provide growth potential in the field of cyclosporine drugs. Furthermore, these players focusing on R&D investments in order to capture a larger share in the market. However, lack of awareness of target disease in developing regions may hamper market growth in the future.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Indication

o By Route of Administration

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape:  Novartis International AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Cyclosporine Market Report by Segment

By Indication

    • Rheumatoid Arthritis

    • Psoriasis

    • Transplant Rejection Prophylaxis

    • Autoimmune Myasthenia Gravis

    • Dry Eye Disease

    • Others

By Route of Administration

    • Oral

    • Parenteral

Global Cyclosporine Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa